X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SANOFI INDIA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SANOFI INDIA ORCHID PHARMA LTD/
SANOFI INDIA
 
P/E (TTM) x -0.1 37.0 - View Chart
P/BV x 0.1 7.0 1.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA LTD   SANOFI INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SANOFI INDIA
Dec-17
ORCHID PHARMA LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1944,945 3.9%   
Low Rs353,901 0.9%   
Sales per share (Unadj.) Rs276.51,081.8 25.6%  
Earnings per share (Unadj.) Rs-79.2141.6 -56.0%  
Cash flow per share (Unadj.) Rs-43.5185.9 -23.4%  
Dividends per share (Unadj.) Rs033.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs53.9868.8 6.2%  
Shares outstanding (eoy) m70.4523.03 305.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.1 10.1%   
Avg P/E ratio x-1.431.2 -4.6%  
P/CF ratio (eoy) x-2.623.8 -11.1%  
Price / Book Value ratio x2.15.1 41.7%  
Dividend payout %023.3 0.0%   
Avg Mkt Cap Rs m8,067101,862 7.9%   
No. of employees `0002.83.2 86.4%   
Total wages/salary Rs m2,5273,685 68.6%   
Avg. sales/employee Rs Th6,956.17,691.9 90.4%   
Avg. wages/employee Rs Th902.51,137.7 79.3%   
Avg. net profit/employee Rs Th-1,993.01,006.5 -198.0%   
INCOME DATA
Net Sales Rs m19,47724,914 78.2%  
Other income Rs m407807 50.5%   
Total revenues Rs m19,88425,721 77.3%   
Gross profit Rs m1,1035,372 20.5%  
Depreciation Rs m2,5191,022 246.5%   
Interest Rs m5,22711 47,516.4%   
Profit before tax Rs m-6,2365,146 -121.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,886 -6.6%   
Profit after tax Rs m-5,5803,260 -171.2%  
Gross profit margin %5.721.6 26.3%  
Effective tax rate %2.036.6 5.5%   
Net profit margin %-28.713.1 -219.0%  
BALANCE SHEET DATA
Current assets Rs m11,01414,432 76.3%   
Current liabilities Rs m32,0606,010 533.4%   
Net working cap to sales %-108.133.8 -319.7%  
Current ratio x0.32.4 14.3%  
Inventory Days Days9561 155.8%  
Debtors Days Days3428 117.8%  
Net fixed assets Rs m29,4407,991 368.4%   
Share capital Rs m705230 305.9%   
"Free" reserves Rs m2,04319,778 10.3%   
Net worth Rs m3,80020,008 19.0%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51027,770 167.5%  
Interest coverage x-0.2468.8 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.9 46.7%   
Return on assets %-0.811.8 -6.5%  
Return on equity %-146.916.3 -901.3%  
Return on capital %-3.725.8 -14.5%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,5136,306 119.1%   
Fx outflow Rs m5,6495,257 107.5%   
Net fx Rs m1,8651,049 177.7%   
CASH FLOW
From Operations Rs m1,6824,351 38.7%  
From Investments Rs m-9,860-787 1,252.9%  
From Financial Activity Rs m6,644-1,884 -352.6%  
Net Cashflow Rs m-1,5351,680 -91.4%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.6 14.4 31.9%  
FIIs % 3.3 14.6 22.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.5 526.7%  
Shareholders   84,811 15,184 558.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  VENUS REMEDIES  STERLING BIOTECH  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Healthcare & IT Stocks Witness Buying(12:30 pm)

Share markets in India have trimmed their early losses and are presently trading marginally lower. Sectoral indices are trading mixed with stocks.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 11, 2018 02:03 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS